Data-driven planning aids in the design of feasible clinical trials from the outset, by simulating enrollment before the ...

In today’s ACT Brief, we examine declining site satisfaction and strategies to improve sponsor-site collaboration, review a ...

FDA has approved Komzifti (ziftomenib) as the first once-daily, oral menin inhibitor for adults with relapsed or refractory NPM1-mutated AML, supported by Phase II KOMET-001 data showing meaningful ...

How sponsors can leverage technology to enhance, not hinder, site efficiency and usability Strategies to incorporate site ...

The ARTISTRY-1 Phase III trial demonstrated that a single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg maintains viral suppression and simplifies therapy for people living with HIV, ...

You have medical affairs being more involved on the research side, engaging with these HCPs to try to create referral ...

In today’s ACT Brief, we look at how artificial intelligence is reshaping drug development decisions across pharma, discuss ...

Advarra and IgniteData have announced a new partnership, enabling secure clinical data transfer between research sites’ instances of Advarra's eSource and electronic data capture (EDC) solutions, ...

ACT: At this year’s SCRS Summit, several site representatives raised concerns about overly complex protocols and patient ...

In today’s ACT Brief, we look at how adaptive trial models are reshaping precision medicine, new data showing Wegovy’s impact ...

As biotechs scale up, streamlining the planning, execution, and monitoring of outsourced clinical trials becomes critical. While CROs manage the day-to-day operations, sponsors are ultimately ...

Alixorexton, an investigational, oral, selective orexin 2 receptor agonist, demonstrated meaningful improvements across the trial’s dual primary endpoints of change from baseline in Maintenance of ...